Search results for "Report"

showing 10 items of 2364 documents

Drosophila SMN2minigene reporter model identifies moxifloxacin as a candidate therapy for SMA

2018

Spinal muscular atrophy is a rare and fatal neuromuscular disorder caused by the loss of alpha motor neurons. The affected individuals have mutated the ubiquitously expressed SMN1 gene resulting in the loss or reduction in the survival motor neuron (SMN) protein levels. However, an almost identical paralog exists in humans: SMN2. Pharmacological activation of SMN2 exon 7 inclusion by small molecules or modified antisense oligonucleotides is a valid approach to treat SMA. Here we describe an in vivo SMN2 minigene reporter system in Drosophila motor neurons that serves as a cost-effective, feasible, and stringent primary screening model for identifying chemicals capable of crossing the conser…

0301 basic medicineMoxifloxacinDrug Evaluation PreclinicalSMN1BiologyBiochemistryAnimals Genetically ModifiedMuscular Atrophy Spinal03 medical and health sciencesExon0302 clinical medicineGenes ReporterGeneticsmedicineAnimalsHumansMolecular BiologyExonsSpinal muscular atrophyMotor neuronSMA*medicine.diseasenervous system diseasesCell biologySurvival of Motor Neuron 2 ProteinAlternative SplicingDisease Models AnimalDrosophila melanogaster030104 developmental biologymedicine.anatomical_structureCajal bodyBlood-Brain BarrierRNA splicing030217 neurology & neurosurgeryBiotechnologyMinigeneThe FASEB Journal
researchProduct

Surveillance of foodborne parasitic diseases in Europe in a One Health approach

2021

In 2012, WHO/FAO ranked 24 foodborne parasites (FBP) using multicriteria decision analysis (MCDA) to provide risk assessors with a basis for prioritising control of highly ranked FBP on the global level. One conclusion was that ranking may differ substantially per region. In Europe, the same methodology was used to rank FBP of relevance for Europe. Of the 24 FBP, the top-five prioritised FBP were identified for Europe as Echinococcus multilocularis, Toxoplasma gondii, Trichinella spiralis, E. granulosus, and Cryptosporidium spp., all of which are zoonotic. The objective of the present study was to provide an overview of surveillance and reporting systems in Europe for these top five priorit…

0301 basic medicineMulticriteria decisionSurveillance dataOriginal Research articleEpidemiology030231 tropical medicineInfectious and parasitic diseasesRC109-216030108 mycology & parasitology3. Good healthFoodborne parasites03 medical and health sciences0302 clinical medicineInfectious DiseasesOne HealthGeographyEnvironmental healthAnimalsUnderreportingParasitologyOne Health surveillanceParasite Epidemiology and Control
researchProduct

Tricho-dento-osseous syndrome and precocious eruption

2017

Tricho-dento-osseous syndrome (TDO), an uncommon form of ectodermal dysplasia is an autosomal dominant genetic disorder which is characterized by inherited defects in tissues arising from epithelial-mesenchymal interaction. Genetic studies have revealed that it is caused by mutation in the DLX3 gene. TDO presents with a great phenotypic heterogeneity and studies have suggested that this heterogeneity is the result of environmental factors or other genetic modifiers. In this article, we report a case of TDO in which the child had typical clinical features of hair, teeth and bone defects, as seen in TDO. Parents of the child were unaffected. Genetic analysis of the child revealed mutation in …

0301 basic medicineMutationPathologymedicine.medical_specialtyEctodermal dysplasiaOral Medicine and PathologyGenetic heterogeneityDLX3Genetic disorderCase ReportBiology:CIENCIAS MÉDICAS [UNESCO]medicine.diseasemedicine.disease_causeGenetic analysisTricho-Dento-Osseous Syndrome03 medical and health sciencesstomatognathic diseases030104 developmental biologyUNESCO::CIENCIAS MÉDICASmedicineGeneral DentistryJournal of Clinical and Experimental Dentistry
researchProduct

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders

2020

Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing–remitting MS (RRMS). We here provide the first case report of primary progressive MS (PPMS) onset upon anti-TNF-α therapy as well as a literature review of previously published cases of anti-TNF-α therapy-associated MS onset. The 51-year old male patient was treated with adalimumab due to psoriasis arthritis. About 18 months after …

0301 basic medicineNecrosisCentral nervous systemprimary progressive multiple sclerosisPrimary Progressive Multiple SclerosisCase ReportAnti-TNF-alpha therapylcsh:RC346-42903 medical and health sciences0302 clinical medicineadalimumabmedicineAdalimumabanti-TNF-alpha therapyDemyelinating DisorderAnti tnf α therapylcsh:Neurology. Diseases of the nervous systemPharmacologybusiness.industry030104 developmental biologymedicine.anatomical_structureNeurologyImmunologyNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct

Ruling out nosocomial transmission of Cryptosporidium in a renal transplantation unit: case report

2016

Background Cryptosporidium spp. is a ubiquitous parasite affecting humans as well as domestic and wild vertebrates, causing diarrhea in both immunocompetent and immunocompromised hosts worldwide. Its transmission occurs primarily by the fecal-oral route. In humans, C. parvum and C. hominis are the most prevalent species, whereas immunocompetent and immunocompromised individuals can also be infected by other zoonotic species. Renal transplant patients are prone to develop cryptosporidiosis, which can induce severe and life-threatening diarrhea. Case presentation We report here a series of nearly concomitant cases of acute symptomatic cryptosporidiosis in three renal transplant patients atten…

0301 basic medicineNephrologyAdultDiarrheaMalemedicine.medical_specialty[SDV]Life Sciences [q-bio]030106 microbiologyCryptosporidiosisCryptosporidiumContext (language use)Case Report03 medical and health sciencesFecesImmunocompromised HostInternal medicinemedicineAnimalsHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyGenotypingCross InfectionbiologyTransmission (medicine)NitazoxanideCryptosporidiumAcute Kidney InjuryMiddle Agedbiology.organism_classificationNitro CompoundsKidney Transplantation3. Good healthTransplantationDiarrheaThiazoles030104 developmental biologyInfectious DiseasesRenal transplant[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyImmunologyCoccidiostatsFemalemedicine.symptomZoonotic speciesmedicine.drugGenotypic species identification
researchProduct

Sensory disturbances of buccal and lingual nerve by muscle compression: a case report and review of the literature

2016

Introduction Several studies on cadavers dissection have shown that collateral branches of the trigeminal nerve cross muscle bundles on their way, being a possible etiological factor of some nerve disturbances. Case Report A 45-year-old man attended to the Temporomandibular Joint and Orofacial Pain Unit of the Master of Oral Surgery and Implantology in Hospital Odontològic of Barcelona University, referring tingling in the left hemifacial región and ipsilateral lingual side for one year, with discomfort when shaving or skin compression. Discussion Several branches of the trigeminal nerve follow a path through the masticatory muscles, being the lingual nerve and buccal nerve the most involve…

0301 basic medicineNervous systemOrofacial painNeuràlgia del trigeminNervi trigeminTrigeminal nerveCase ReportOdontologíaMalalties de la bocaOrofacial pain-TMJD03 medical and health sciencesstomatognathic systemCadavermedicineSistema nerviósGeneral Dentistrymedicine.cranial_nerveLingual nerveTrigeminal nervebusiness.industryAnatomy:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludMasticatory forceTemporomandibular jointDissectionstomatognathic diseasesmedicine.anatomical_structureMouth diseasesUNESCO::CIENCIAS MÉDICAS030101 anatomy & morphologyBuccal nervemedicine.symptombusinessTrigeminal neuralgia
researchProduct

Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.

2020

PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E–mutated glioma treated with BRAF inhibition across 29 centers from multiple countries. RESULTS Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyHematologyendocrine system diseasesbusiness.industrydigestive system diseases3. Good healthBRAF V600E03 medical and health sciencesenzymes and coenzymes (carbohydrates)030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineMutation (genetic algorithm)Original Reportsmedicinebusinessskin and connective tissue diseasesneoplasmsChemoradiotherapyJCO precision oncology
researchProduct

Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gef…

2019

The management of multiple primary cancers, an event not so infrequent in oncology practice, is a critical issue due to the lack of literature. In this study, we reported the case of a patient with non-small cell metastatic lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) who received gefitinib in combination with gemcitabine plus nab-paclitaxel and with mFOLFOX6 in first and second line, respectively. It achieved a progression-free survival and a28-months overall survival (OS) for NSCLC and PFS-1 and OS of 20 and 13 months, respectively for PDAC. Moreover, the combination of gefitinib and chemotherapy treatmentsshowed a good safety profile. Given the insignificant frequency …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentCellgefitinibpancreatic ductal adenocarcinomaCase Reportmedicine.disease_causechemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineGefitinibInternal medicinemedicineLung cancerSurvival ratenon-small cell lung cancerChemotherapyMutationbusiness.industrydouble primary cancersLong Term Survivormedicine.diseaseDouble primary cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensGemcitabine030104 developmental biologymedicine.anatomical_structureOncologyB7-H3030220 oncology & carcinogenesisbusinessmedicine.drugCancers
researchProduct

Myositis/myasthenia after pembrolizumab in a bladder cancer patient with an autoimmunity-associated HLA: Immune–biological evaluation and case report

2021

Pembrolizumab (mAb to PD-1) has been recently approved for the therapy of pretreated urothelial cancer. Despite the efficacy, it is often accompanied by unpredictable and sometime severe immune-related (ir) adverse events (AEs). Here, we report the clinical and immune–biological characterization of a patient with a metastatic bladder cancer who developed myositis signs (M) and a myasthenia-like syndrome (MLS) during treatment with pembrolizumab. The patient presented an autoimmunity-associated HLA haplotype (HLA-A*02/HLA-B*08/HLA-C*07/HLA-DRB1*03) and experienced an increase in activated CD8 T-cells along the treatment. The symptomatology regressed after pembrolizumab discontinuation and a …

0301 basic medicineOncologyMaleCase ReportAutoimmunityPembrolizumabPD1-checkpoint inhibitorsmedicine.disease_causeAutoimmunity0302 clinical medicineAntineoplastic Agents ImmunologicalBiology (General)HLA AntigenMyositiPD1-checkpoint inhibitorSpectroscopyMyositisGeneral MedicineComputer Science ApplicationsMyasthenia GraviChemistryPyridostigmineurothelial cancer030220 oncology & carcinogenesisUrinary Bladder NeoplasmClass-I/II HLAMyastheniamedicine.drugHumanmedicine.medical_specialtyQH301-705.5PrognosiHuman leukocyte antigenAntibodies Monoclonal HumanizedCatalysisInorganic Chemistry03 medical and health sciencesInternal medicinemedicinePhysical and Theoretical ChemistryAdverse effectMolecular BiologyQD1-999Agedbusiness.industryOrganic ChemistryCancermedicine.diseaseDiscontinuation030104 developmental biologybusiness
researchProduct

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After All…

2020

Currently, the prognosis of Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients relapsing after an allogenic hematopoietic stem cell transplantation (allo-SCT) remains poor, with few therapeutic options available. Here we present the case of a 32 years old patient with dasatinib-resistant post-transplant molecular relapse of ALL, who received, as second-line therapy, the combination of ponatinib and donor lymphocyte infusion (DLI). The therapy was safe and the patient achieved a sustained minimal residual disease negative disease, still ongoing after 22 months, which was accompanied by several changes in the immune populations distribution within the bone marrow (i.e., the increase in the C…

0301 basic medicineOncologymedicine.medical_specialtyCancer Researchmedicine.medical_treatmentT lymphocytesCase ReportHematopoietic stem cell transplantationlcsh:RC254-282Donor lymphocyte infusionbone marrow microenviroment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineacute lymhoblastic leukemiaInternal medicinehemic and lymphatic diseasesT lymphocytemedicineponatinibbusiness.industryPonatinibDonor Lymphocyteslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDasatinib030104 developmental biologymedicine.anatomical_structurechemistryOncology030220 oncology & carcinogenesisdonor lymphocyte infusion (DLI)Bone marrowStem cellbusinessCD8medicine.drugFrontiers in Oncology
researchProduct